About Us
At CUREator, we aim to transform promising biomedical research opportunities into clinical and market-ready solutions that benefit patients, provide a return on national research investment, and grow the Australian biotech industry.
We provide non-dilutive grant funding and advice to new biotech spinouts derived from academic research and small to medium-sized biotech enterprises with commercial potential.
CUREator is managed by the Brandon BioCatalyst and uses the established review processes from this investment model to help companies achieve key technical and commercial milestones, to secure follow-on investments or partnerships.
Opportunity
Australia boasts world-leading medical research and clinical capabilities, supported by significant government funding. However, many groundbreaking innovations lack the initial financial support and expertise to become ‘investment-ready’ opportunities.
Early funding pathways and expert assistance are crucial to bridging this gap and growing the Australian biotech sector.
CUREator leverages Brandon BioCatalyst’s experience in managing the development, translation, and commercialisation of biomedical discoveries to ensures thorough technical and commercial due diligence, expert advice, and independent investment insights.
We seek out the most promising Australian biotech innovations, providing them with the funding and support they need to succeed and grow the Australian biotech industry.
Team
CUREator adopts the established review processes of the Brandon BioCatalyst investment model, ensuring thorough due diligence, expert advice, and independent investment insights. CUREator seeks the most promising and impactful Australian biotech innovations and looks to provide them with funding and support.
